Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA312
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Recommendations

1.1

Alemtuzumab is recommended as an option, within its marketing authorisation, for treating highly active relapsing–remitting multiple sclerosis in adults with:

  • highly active disease despite a full and adequate course of treatment with at least 1 disease-modifying therapy, or

  • rapidly evolving severe relapsing–remitting multiple sclerosis defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity.